Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

May 1, 2024

Conditions
Post Operative Pain
Interventions
DRUG

Liposomal bupivacaine

Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.

DRUG

0.5% bupivacaine with 1:100,000 epinephrine

Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.

Trial Locations (1)

90089

Herman Ostrow School of Dentistry of USC, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER